Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL
Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL
177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC
Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma
Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps
Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC
Tarlatamab improves brain metastases control and survival compared to chemo in SCLC
miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours
Implanted tile-based radiation shows promise compared with stereotactic radiotherapy for brain metastases
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC
ASCO 2026: Latest updates in mRCC
Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer
ASCO 2026: Breast cancer overview